Critical Review: Ayala Pharmaceuticals (NASDAQ:ADXS) and Nuvo Pharmaceuticals (OTCMKTS:MRVFF)

Volatility & Risk

Ayala Pharmaceuticals has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Comparatively, Nuvo Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Profitability

This table compares Ayala Pharmaceuticals and Nuvo Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Nuvo Pharmaceuticals	20.88%	-1,996.22%	14.25%

Institutional and Insider Ownership

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Comparatively, 7.0% of Nuvo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Ayala Pharmaceuticals and Nuvo Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24 million	11.05	-$48.07 million	($5.02)	-0.12
Nuvo Pharmaceuticals	$54.98 million	0.20	-$25.70 million	($0.12)	-8.16

Nuvo Pharmaceuticals has higher revenue and earnings than Ayala Pharmaceuticals. Nuvo Pharmaceuticals is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Nuvo Pharmaceuticals beats Ayala Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

About Nuvo Pharmaceuticals

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.